Medicare Clintonfraud

By Roberts, Paul Craig | The Washington Times (Washington, DC), August 2, 1999 | Go to article overview
Save to active project

Medicare Clintonfraud

Roberts, Paul Craig, The Washington Times (Washington, DC)

President Clinton's Medicare drug proposals would be the beginning of the end of quality health care for the elderly. Mr. Clinton's plan would result in price controls and rationing, and it would slow, and eventually stop, the development of new drugs.

Mr. Clinton, Hillary, and HHS Secretary Donna Shalala all deny this. But how would they know? Who is there in the Clinton administration to tell them?

What Mr. Clinton is doing is trying to block a tax cut by saying the alternative use of the money is a drug prescription giveaway to the elderly.

Mr. Clinton's proposal will result in price controls, because it would divide the country into regions and award contracts for administering the drug program. Various entities - HMOs, drug chains - would bid for the contract.

Cost, of course, would be a factor in the bids. In competing for the contract, bidders would devise ways in which drug coverage would be restricted to prevent open-ended costs.

There is no way that this can be done except by limiting payments for drugs

and by restricting patients' access to medicines.

Squeezing drug prices helps the bureaucrats administering the program stay within budget. But squeezing the pharmaceutical companies would jeopardize the expensive research required to develop life-enhancing medicines.

Bureaucrats and "consumer activists" often complain that the price of a particular drug is far above the cost of producing it once it is in production. This is very often the case. But it does not mean that drug companies are ripping off patients or Medicare.

It costs a lot to develop new medicines. Many don't pan out, and the ones that do must go through lengthy trials and Food and Drug Administration approval procedures. The medicines that do pan out have to carry the costs of the failures and the federal regulation as well as their own production costs. Otherwise, the efforts of pharmaceutical companies to develop new medicines will result in losses. It is much safer to concentrate on producing and improving existing products.

Squeezing prices paid to pharmaceutical companies squeezes their profits and ability to carry on the development of new medicines. This is not what we want.

When medicines are supplied free or at subsidized prices, the demand increases.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Cite this article

Cited article

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited article

Medicare Clintonfraud


Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?